Scholarlink

<p>Tinengotinib is a spectrum-selective multi-kinase inhibitor targeting FGFR1–3, JAK1/2, VEGFRs, and Aurora A/B kinases. This phase Ib/II clinical trial (<a href="https://clinicaltrials.gov/study/NCT05253053">NCT05253053</a>) evaluated tinengotinib as monotherapy (Arm A, <i>n</i> = 53, in Chinese patients with advanced solid tumors) and in combination with atezolizumab (Arm B, <i>n</i> = 31, in patients with advanced biliary tract cancer). Each arm comprised a dose-escalation phase with standard 3 + 3 design (phase Ib) followed by a dose-expansion phase (phase II). The primary endpoints of the phase Ib were safety, tolerability, dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and dose selection for expansion, with secondary endpoints of efficacy (phase II) and pharmacokinetics. The trial met pre-specified primary endpoints: tinengotinib was well tolerated without DLTs, and MTD was not reached. Tinengotinib demonstrated antitumor activity both as monotherapy (objective response rate [ORR]: 16.7% in Arm A) and combined with atezolizumab (ORR: 22.6% in Arm B). In predefined exploratory subgroup analysis, notable efficacy was observed in cholangiocarcinoma (ORR: 30.8% in Arm A [<i>n</i> = 13]; 25.0% in Arm B [<i>n</i> = 28]). Tinengotinib monotherapy achieved favorable response in cholangiocarcinoma harboring <i>FGFR2</i> fusion progressing on prior FGFR inhibitor (ORR: 66.7%). In patients with cholangiocarcinoma previously treated with immune checkpoint inhibitors (<i>n</i> = 20), the combination regimen achieved an ORR of 20.0% and a disease control rate of 75.0%. These findings support further development of tinengotinib, both as monotherapy and in combination with immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月11日

查看全文
  • Panpan Zhang,
  • Zuoxing Niu,
  • Hongqian Guo,
  • Miao Zhang,
  • Shusuan Jiang,
  • Baoshan Cao,
  • Chaohong He,
  • Xinfang Hou,
  • Jian Zhang,
  • Jiajia Yuan,
  • Yujia Zhu,
  • Yingying Yu,
  • Caixia Sun,
  • Peng Peng,
  • Jean Fan,
  • Jifang Gong,
  • Jun Zhou,
  • Lin Shen

摘要

Tinengotinib is a spectrum-selective multi-kinase inhibitor targeting FGFR1–3, JAK1/2, VEGFRs, and Aurora A/B kinases. This phase Ib/II clinical trial (NCT05253053) evaluated tinengotinib as monotherapy (Arm A, n = 53, in Chinese patients with advanced solid tumors) and in combination with atezolizumab (Arm B, n = 31, in patients with advanced biliary tract cancer). Each arm comprised a dose-escalation phase with standard 3 + 3 design (phase Ib) followed by a dose-expansion phase (phase II). The primary endpoints of the phase Ib were safety, tolerability, dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and dose selection for expansion, with secondary endpoints of efficacy (phase II) and pharmacokinetics. The trial met pre-specified primary endpoints: tinengotinib was well tolerated without DLTs, and MTD was not reached. Tinengotinib demonstrated antitumor activity both as monotherapy (objective response rate [ORR]: 16.7% in Arm A) and combined with atezolizumab (ORR: 22.6% in Arm B). In predefined exploratory subgroup analysis, notable efficacy was observed in cholangiocarcinoma (ORR: 30.8% in Arm A [n = 13]; 25.0% in Arm B [n = 28]). Tinengotinib monotherapy achieved favorable response in cholangiocarcinoma harboring FGFR2 fusion progressing on prior FGFR inhibitor (ORR: 66.7%). In patients with cholangiocarcinoma previously treated with immune checkpoint inhibitors (n = 20), the combination regimen achieved an ORR of 20.0% and a disease control rate of 75.0%. These findings support further development of tinengotinib, both as monotherapy and in combination with immunotherapy.